Clinical Trial Update: T-Cell Depleted Double UCB for Refractory AML [Phase 2]

View source ↗

Summary

Phase 2 trial of T-cell depleted double umbilical cord blood for refractory acute myeloid leukemia has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• T-cell depleted double umbilical cord blood

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2015-05-15